LBPH: Longboard Pharmaceuticals, Inc. Total Debt to Capital

Driven by the success of bexicaserin, Longboard Pharmaceuticals (LBPH) maintains the loyalty of leading neurobiologists, which this chart of the market price on GURU.Markets captures at 0.01. The business relies on the development of unique, patent-protected epilepsy medications. Meanwhile, management effectively invests funds into scientific advancements while strictly adhering to medical trial protocols to secure regulatory approval.

This ratio determines the proportion of borrowed funds relative to equity, reflecting the degree of financial leverage and the risk of business dependence on creditors. By analyzing the historical changes in the total debt-to-equity ratio, an investor assesses the resilience of Longboard Pharmaceuticals (LBPH) to debt load, which is critically important during the aggressive expansion of R&D capabilities to outperform competitors in the rare neurological pathology therapy segment.